Association of CD58 Polymorphism with Multiple Sclerosis and Response to Interferon B Therapy in A Subset of Iranian Population

Objective: multiple sclerosis (ms) is one of the leading neurodegenerative causes ofphysical disability world-wide. genetic aberrations of autoimmunity pathway componentshave been demonstrated to significantly influence ms development. cluster of differentiation58 (cd58) is pertained to a group of genes which had been assayed in several recentassociation studies. given the significance of cd58 in modulation of t regulatory cellsthat control autoimmune responses, the present study was conducted to investigate thefrequency of rs12044852 polymorphism and its effect on the outcome of interferon beta(ifn-b) therapy in a subset of iranian ms patients.materials and methods: two hundred ms patients and equal number of healthycontrols were recruited to be genotyped in an experimental case-control based studythrough polymerase chain reaction using specific sequence primers (pcr-ssp). relapsingremitting multiple sclerosis (rrms) patients administered ifn-b therapy werefollowed up with clinical visits every three months up to two years. the mean of multiplesclerosis severity score (msss) and expanded disability status scale (edss)were measured to monitor the change in severity of ms in response to ifn-b therapy.pearson’s chi-square and analysis of variance (anova) tests were the main statisticalmethods used in this study.results: strong association was found between the cc genotype and onset of ms(p=0.001, or=2.22). however, there was no association between rs12044852 andvarious classifications and severity of ms. pharmacogenetics-based analysis indicatedthat carriers of cc genotype had the highest msss score compared to others,implying a negative impact of rs12044852 on response to ifn-b t herapy.conclusion: taken together, our findings revealed the critical effect of rs12044852 polymorphismof cd58 on the progression of ms disease. this indicates that genotyping ofms patients may expedite achieving personalized medical management of ms patients.